Making Sense of Melanoma Adjuvant Treatment in the Absence of OS Data
Source: Medscape, June 2025
We will finalize this series on where we should go, and what’s next in terms of immunotherapy in the adjuvant setting, by looking into the two other aspects that we need to consider when we discuss the factthat there is no overall survival benefit nor are there data on the overall survival benefit for patients treated with immunotherapy in the adjuvant setting.
We discussed the first one, which was the fact that there might be some discussions or some uncertainties in terms of the reimbursement because these data are not available yet and might only be available in 2028.
You must be logged in to post a comment.